natgillin/translations-raw huggingface dataset:
Median PFS i måneder (95% CI)
Median PFS in months (95% CI)
Median PFS i måneder [95% CI] 18,5 [16,5; 21,4] 14,3 [12,0; 16,0]
Median PFS in months [95% CI] 18.5 [16.5, 21.4] 14.3 [12.0, 16.0]
Median PFS på data cutoff var 19,3 måneder (95% CI: 14,8; NR).
The median PFS at the time of data cutoff was 19.3 months (95% CI: 14.8, NR).
Median PFS var højere hos patienter med kun 13p deletion behandlet med MabCampath (24,4 v 13,0 måneder; p=0,0170 stratificeret efter Rai-stadium).
Median PFS was superior in patients with sole 13q deletion treated with MabCampath (24.4 v 13.0 months; p=0.0170 stratified by Rai Stage).
Median PFS1, uger
Median PFS1, weeks
Median plasma hiv-1 RNA log10 kopier/ml
Median plasma HIV-1 RNA log10 copies/mL
Median plasma hiv-1-rna ved baseline (interval) log10 kopier/ml
Median baseline plasma HIV-1 RNA (range) log10 copies/mL
Median progressionsfri overlevelse
Median progression free survival
Median progressionsfri overlevelse (måneder)
Median Progression
Median progressionsfri overlevelse (måneder) (95 % CI)
Median progression-free survival (months) (95% CI)
Median progressionsfri overlevelse (måneder) (95% CI)
Median PFS (months) (95% CI)
Median progressionsfri overlevelse (måneder) (95% konfidensinterval)
Median PFS (months) (95% CI)
Median progressionsfri overlevelse, måneder (95 % CI)
Median Progression-free Survival, months (95% CI)
Median progressionsfri overlevelse, måneder (95 % CI)
Progression-free survival, median, months (95% CI)
Median punkturfri overlevelse (dage)
Median puncture-free survival (days)
Median reduktion i procent i daglig OCS-dosis i forhold til baseline (95 % konfidensinterval)
Median % reduction in daily OCS dose from baseline (95% CI)
Median responsvarighed
Median duration of
Median responsvarighed
Median duration of response
Median responsvarighed
Median time to response
Median responsvarighed (mdr.) (95 % CI)
Median Duration of response (months) (95% CI)
Median responsvarighed [måneder (95 % CI)]
Median Duration of Response [months (95% CI)]
Median responsvarighed hos patienter med PD-L1-tumorekspressionsniveau ≥5% blev ikke nået (0+-22,3+) i kombinationsarmen, var 20,8 måneder (2,8-20,8) i nivolumab-monoterapi-armen og blev ikke nået (1,4-19,9+) i ipilimumab-armen.
Median durations of response for patients with tumour PD-L1 expression level ≥5% were not reached (range: 0+-22.3+) in the combination arm, 20.8 months (range: 2.8-20.8) in the nivolumab monotherapy arm and not reached (range: 1.4-19.9+) in the ipilimumab arm.
Median responsvarighed, måneder (95 % CI)
Duration of response, median, months (95% CI)
Median rPFS i måneder (95 % KI)
Median rPFS in months (95% CI)
Median samlet overlevelse
Median overall survival
Median samlet overlevelse (95 % SI)
Median OS (95% CI)
Median samlet overlevelse (95% CI) (måneder)
Median overall survival (95% CI) (months)
Median samlet overlevelse (dage)
Median overall survival (days)
Median samlet overlevelse (i måneder) (95 % KI)
Median overall survival in months (95% CI)
Median samlet overlevelse (måneder)
Median OS (months)
Median samlet overlevelse (måneder)
Median overall survival (months) (95% CI)
Median samlet overlevelse (måneder) (95% konfidensinterval)
Median OS, (months) (95 % CI)
Median samlet overlevelse =
Median OS = 5.06 months
Median samlet overlevelse = 5,93 måneder
Median OS = 5.93 months
Median samlet overlevelse = 6,0
Median OS = 6.0 months
Median samlet overlevelse = 6,4 måneder
Median OS = 6.0 months
Median samlet overlevelse = 6,4 måneder
Median OS = 6.4 months
Median samlet overlevelse i ”intent-to-treat-populationen” var 7,6 måneder (95 % CI: 5,7, 11,5).
The median overall survival in the intent-to-treat population was 7.6 months (95% CI: 5.7, 11.5).
Median samlet overlevelse i ”intent-to-treat-populationen” var 7,7 måneder hos forsøgspersoner, der fik Dacogen, sammenlignet med 5,0 måneder hos forsøgspersoner i TC-gruppen (hazard ratio 0,85; 95 % CI: 0,69, 1,04, p < 0,1079).
The median overall survival in the intent-to-treat population was 7.7 months in subjects treated with Dacogen compared to 5.0 months for subjects in the TC arm (hazard ratio 0.85; 95% CI: 0.69, 1.04, p = 0.1079).
Median samlet overlevelse var 62 uger for topotecan versus 53 uger for paclitaxel (risiko ratio 0,9 [0,6; 1,3]).
Median overall survival was 62 weeks for topotecan versus 53 weeks for paclitaxel (hazard ratio 0.9 [0.6, 1.3]).
Median samlet overlevelse var 62 uger for topotecan versus 53 uger for paclitaxel (risiko ratio 0,9 0,6; 1,3).
Median overall survival was 62 weeks for topotecan versus 53 weeks for paclitaxel (hazard ratio 0.9 [0.6, 1.3]).
Median samlet overlevelse var 62 uger for topotecan versus 53 uger for paclitaxel (risikoforhold 0,9 [0,6; 1,3]).
Median overall survival was 62 weeks for topotecan versus 53 weeks for paclitaxel (hazard ratio 0.9 [0.6, 1.3]).
Median samlet overlevelse*
Median overall survival
Median samlet overlevelse, måneder (95 % CI)
Overall survival, median, months (95% CI)
Median samlet overlevelse, måneder (95% CI)
Median Overall Survival, months (95% CI)
Median serum pegfilgrastim konc (ng/ml)
Median Serum Pegfilgrastim Conc. (ng/ml)
Median SO (måneder)
Median OS (months)
Median steady-state pazopanib Cmax og AUC(0-24) hos patienter med let afvigende leverparametre (defineret som enten normalt bilirubin-niveau og alle grader af forhøjet ALAT eller forhøjet bilirubin- niveau op til 1,5 gange den øvre normalgrænse uanset ALAT-niveau) efter administration af 800 mg pazopanib én gang daglig, svarede til medianen hos patienter med normal leverfunktion (se tabel 7).
The median steady-state pazopanib Cmax and AUC(0-24) in patients with mild abnormalities in hepatic parameters (defined as either normal bilirubin and any degree of ALT elevation or as an elevation of bilirubin up to 1.5 x ULN regardless of the ALT value) after administration of 800 mg once daily are similar to the median in patients with normal hepatic function (see Table 7).
Median stigning i CD4 celletal ved uge 48 (celler/mm3)
Median increase in CD4 cell count at week 48 (cells/mm3)
Median stigning i CD4 fra baseline (x 106 celler/l)
CD4 median increase from baseline (x 106 cells/L)
Median stigning i Hgb, g/dl (mmol/l)
Median Increase in Hgb, g/dL
Median tid (måneder)
Median time (months)
Median tid for samlet overlevelse var 62 uger for topotecan versus 53 uger for paclitaxel (risiko ratio 0,9 [0,6, 1,3 ].
Median overall survival was 62 weeks for topotecan versus 53 weeks for paclitaxel (hazard ratio 0.9 [0.6, 1.3]).
Median tid fra diagnose til behandlingsstart var 18 måneder.
The median time from diagnosis to start of treatment was 18 months.
Median tid fra diagnose til første dosis, år (interval)
Median time from diagnosis to first dose, years (range)
Median tid fra diagnose til randomisering var 64 måneder i dasatinib-gruppen og 52 måneder i imatinib- gruppen.
The median time from diagnosis to randomisation was 64 months in the dasatinib group and 52 months in the imatinib group.
Median tid fra diagnose til start af behandling var 28 måneder.
The median time from diagnosis to start of treatment was 28 months.
Median tid fra diagnose til start af behandling var 48 måneder.
The median time from diagnosis to start of treatment was 48 months.
Median tid til første behov for terapeutisk ascitespunktur (dage)
Median time to first need for therapeutic ascites puncture (days)
Median tid til første tilbagegang af WHO performance status var signifikant længere i TPF-armen end med PF.
Median time to first deterioration of WHO performance status was significantly longer in the TPF arm compared to PF.
Median tid til MMR var efter 60 måneders opfølgning 9,3 måneder i SPRYCEL-gruppen og 15,0 måneder i imatinib-gruppen hos patienter med en MMR.
Median time to MMR after 60 months of follow-up was 9.3 months in the SPRYCEL group and 15.0 months in the imatinib group in patients with a MMR.
Median tid til progression (uger) (95 % CI)
Median time to progression (weeks) (95% CI)
Median tid til progression (uger)** (95% konfidensinterval)
Median time to progression (weeks)** (95% CI)
Median tid til respons var 13 uger (95% konfidensinterval 12-23).
Median time to response was 13 weeks (95% C.I. 12–23).
Median tid til svigtende behandling hos respondenter var 122 uger (95% konfidensinterval 106-147), mens i den overordnede studiepopulation var 84 uger (95% konfidensinterval 71-109).
Median time to treatment failure in responders was 122 weeks (95% C.I 106–147), while in the overall study population it was 84 weeks (95% C.I 71–109).
Median tid til tab af respons efter uge 54
Median time to loss of response
Median tid til tab af respons frem til uge 54
Median time to loss of
Median tid til tab af respons frem til uge 54
Median time to loss of response
Median tid til tumorprogression
Median time to tumour
Median tid til tumorprogression
Median time to tumour progression (months) (95 % CI)
Median tid til tumorprogression (måneder)
Median time to tumour progression (months)
Median tiden fra start af induktionsbehandling med pemetrexed og cisplatin til start af vedligeholdelsesbehandling var 2,96 måneder i både pemetrexed- og placeboarmen.
The median time from the start of pemetrexed plus cisplatin induction therapy to the start of maintenance treatment was 2.96 months on both the pemetrexed arm and the placebo arm.
Median total overlevelse
Median overall survival
Median total overlevelse (måneder)
Median overall survival (months) (95% CI)
Median total overlevelse (uger) (95% konfidensinterval)
Median overall survival (weeks) (95% CI)
Median total overlevelse for den totale population (n=663) var 13,4 måneder for pemetrexed-armen og 10,6 måneder for placeboarmen, hazard ratio = 0,79 (95 % CI= 0,65-0,95; p=0,01192).
The median OS for the overall population (n = 663) was 13.4 months for the pemetrexed arm and 10.6 months for the placebo arm, hazard ratio = 0.79 (95% CI = 0.65-0.95, p = 0.01192).
Median TTF/PFS/ EFS,
Median TTF/PFS/ EFS
Median TTP (mdr.) (95 % CI)
Median TTP (months) (95% CI)
Median TTP (måneder)
Median TTP
Median TTP (måneder)
Median TTP (months)
Median TTP (måneder)
Median TTP (months) (95% CI)
Median TTP, uger
Median TTP, weeks
Median var 4 serier af vedligeholdelsesbehandling med pemetrexed og 4 serier med placebo.
Patients received a median of 5 cycles of maintenance treatment with pemetrexed and 3.5 cycles of placebo.
Median var 5 serier vedligeholdelsesbehandling med pemetrexed og 3,5 serier med placebo.
Patients received a median of 5 cycles of maintenance treatment with pemetrexed and 3.5 cycles of placebo.
Median varighed af fuldstændigt TMA-respons, uger (interval)1
Median duration of complete TMA response, weeks (range) 1
Median varighed af hæmatologisk normalisering, uger (interval)1
Median duration of hematologic normalization, weeks (range) 1
Median varighed af intrakraniel respons, måneder (95 % CI)
Duration of intracranial response, median, months (95% CI)
Median varighed af progressionsfri overlevelse (måneder) (95% konfidensinterval)
Median duration (months) of PFS (95% CI)
Median varighed af remission (uger) (95% konfidensinterval)
Median duration of remission (weeks) (95% CI)
Median varighed af respons
Median duration of response
Median varighed af respons (måneder)
Median Duration of
Median varighed af respons på kemoterapi ± strålebehandling (mdr.) (95 % CI)
Median duration of response to chemotherapy ± radiotherapy (months) (95% CI)
Median varighed af respons til kemoterapi ± strålebehandling (måneder) (95
Median duration of response to chemotherapy ±
Median varighed af respons til kemoterapi ± strålebehandling (måneder) (95 % CI)
Median duration of response to chemotherapy ± radiotherapy (months)
Median varighed af respons til kemoterapi ± strålebehandling (måneder) (95 %CI)
Median duration of response to chemotherapy ±
Median varighed af respons, alle patienter, måneder
Median Duration of Response, all Patients, months
Median varighed af tidligere ART-eksponering, uger
Median duration of prior ART exposure, weeks
Median varighed af transfusionsuafhængighed (uger)
Median Duration of Transfusion Independence (weeks)
Median varighed dage (måneder)
Median duration Days (months)
Median varigheden for samlet overlevelse var 29,9 måneder i trastuzumabemtansin-armen sammenlignet med 25,9 måneder for lapatinib plus capecitabin-armen.
The median duration of overall survival was 29.9 months in the trastuzumab emtansine arm compared with 25.9 months in the lapatinib plus capecitabine arm.
Median ændring fra baseline i CD4-celler (celler/µl)
Median Change from baseline in CD4 cells (cells/l)
Median ændring fra baseline i CD4-celler (celler/μl), observeret analyse
Median change from baseline in CD4 cells (cells/μl), observed analysis
Median ændring i myomvolumen fra baseline til uge 13a
Median change in myoma volume from baseline to week 13a
Median ændring i myomvolumen i forhold til baseline
Median change in myoma volume from baseline
Median ændring vRNA (log10 c/ml)
Median Change vRNA (log10 c/ml)
Median – måneder (95 % CI)
Median – months (95 % CI)
Median – måneder (95 % CIa)
Median – months (95 % CIa)
Median – måneder (95 % KI)
Median – months (95% CI)
Median, alle patienter
Median, all patients
Median, måneder
Median, months
Median, måneder (95 % KI)
Median, Months (95% CI)
Median, uger (95 % CI)
Median, wks (95% CI)
Median, år (interval)
Median, years (range)
Median- tiden for tilbagefald (tilbagevenden af albumin-korrigeret serum-calcium til mere end 3 mmol/l) var 18-26 dage.
The median time to relapse (return of albumin-corrected serum calcium above 3.0 mmol/l) was 18 to 26 days.
Median-antallet af cyklusser administreret pr. patient var 6 (med en range på 1-16) for TCF-armen sammenlignet med 4 (med en range på 1-12) for CF-armen.
The median number of cycles administered per patient was 6 (with a range of 1-16) for the TCF arm compared to 4 (with a range of 1-12) for the CF arm.
Median-antallet af cyklusser administreret pr. patient var 6 (med et interval på 1-16) for TCF-armen sammenlignet med 4 (med et interval på 1-12) for CF-armen.
The median number of cycles administered per patient was 6 (with a range of 1-16) for the TCF arm compared to 4 (with a range of 1-12) for the CF arm.
Median-OS (mdr.) (95 % CI)
OS months median (95% CI)
Median-OS (samlet medianoverlevelse) var 9,8 måneder.
The median overall survival (OS) was 9.8 months.
Median-OS ikke nået for begge grupper
Median OS not reached for both arms
Median-OS var 30,8 måneder (95% CI; 25,2-36,5 måneder) patienter i monoterapi med bortezomib og 33,0 måneder (95% CI; 28,9-37,1 måneder) for patienter i kombinationsbehandling med bortezomib plus pegyleret liposomal doxorubicin.
The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the bortezomib monotherapy patients and 33.0 months (95% CI; 28.9-37.1 months) for the bortezomib plus pegylated liposomal doxorubicin combination therapy patients.
Median-OS, måneder (95 % CI)
Median months OS (95% CI)
Median-PFS (mdr.) (95 % CI)
PFS months median (95% CI)
Median-PFS (måneder) (95 % CI)
Median PFS (months) (95% CI)
Median-PFS var 15,7 måneder for patienter behandlet med enzalutamid versus 5,8 måneder for patienter behandlet med bicalutamid [HR = 0,44 (95 % KI: 0,34; 0,57), p < 0,0001].
Median PFS was 15.7 months for patients on enzalutamide versus 5.8 months for patients on bicalutamide [HR = 0.44 (95% CI: 0.34, 0.57), p < 0.0001].
Median-PFS var 3,7 måneder (95% CI: 1,9; 9,3).
The median PFS was 3.7 months (95% CI: 1.9, 9.3).
Median-rPFS i måneder (95 % KI)
Median rPFS in months (95% CI)
Median-tid til tumorprogression
Median time to tumour progression
Median-tid til tumorprogression
Median time to tumour progression (months)
Median-tid til tumorprogression (måneder)
Median time to tumour progression (months)
Median-tiden fra start af ALIMTA og cisplatin-induktionsbehandling til start af vedligeholdelsesbehandling var 2,96 måneder i både pemetrexed- og placeboarmen.
The median time from the start of ALIMTA plus cisplatin induction therapy to the start of maintenance treatment was 2.96 months on both the pemetrexed arm and the placebo arm.
Median-tiden fra start af pemetrexed og cisplatin- induktionsbehandling til start af vedligeholdelsesbehandling var 2,96 måneder i både pemetrexed- og placeboarmen.
The median time from the start of pemetrexed plus cisplatin induction therapy to the start of maintenance treatment was 2.96 months on both the pemetrexed arm and the placebo arm.
Median-tiden til progression af disse endpoints varierede fra at være 0,7 til 2,1 måneder længere for TMZ end for procarbazin (log rank p = < 0,01 til 0,03).
The HR median times to progression in these endpoints ranged from 0.7 to 2.1 months longer for TMZ than for procarbazine (log rank p = < 0.01 to 0.03).
Median-TTP var 6,5 måneder for patienterne, der fik bortezomib-monoterapi, sammenlignet med 9,3 måneder for de patienter, der fik Caelyx plus bortezomib-kombinationsbehandling.
6.5 months for the bortezomib monotherapy patients compared with 9.3 months for the Caelyx plus bortezomib combination therapy patients.
Median; (Q1, Q3) (IE/dL / IE/kg)
Median; (Q1; Q3) (IU/dL / IU/kg)
Mediana (95 % CI)
Median
Mediana (95 % CI)
Mediana (95% CI)
Mediana (95 % CI)b
Mediana (95% CI)b
Mediana OS-tid, måneder (95 % CI)
Mediana OS time, months (95% CI)
Mediana OS-tid, måneder (95 % CI)b
Mediana OS time, months (95% CI)b
Mediana PFS-tid, måneder (95 % CI)
Mediana PFS time, months (95% CI)
Mediana PFS-tid, måneder (95 % CI)b
Mediana PFS time, months (95% CI)b
Mediana PFS2-tid, måneder (95 % CI)
Mediana PFS2 time, months (95% CI)
Medianalder (år)
Median Age (years)
Medianalder for patienter randomiseret til trastuzumabemtansin var 53 år; de fleste patienter var kvinder (99,8%), størstedelen var kaukasere (72%), og 57% havde østrogen-receptor- og/eller progesteron-receptor- positiv sygdom.
For patients randomised to trastuzumab emtansine, the median age was 53 years, most patients were female (99.8%), the majority were Caucasian (72%), and 57% had oestrogen-receptor and/or progesterone-receptor positive disease.
Medianalder, år (min.-maks.)
Median age, years (min-max)
Medianalderen for de 162 rekrutterede patienter var 46 år (interval 20 til 67 år).
Median (range) CD4 cell count at baseline was
Medianalderen for den totale population var 9,5 år (aldersinterval for Votubia-armen: 1,0 til 23,9; aldersinterval for placebo-armen: 0,8 til 26,6), 69,2 % af patienterne var 3 til <18 år og
The median age for the total population was 9.5 years (age range for the Votubia arm: 1.0 to 23.9; age range for the placebo arm: 0.8 to 26.6), 69.2% of the patients were aged 3 to
Medianalderen var 34 år og omkring 64 % af patienterne var mænd, median CD4-celletallet var 170 og 190 celler pr mm3 i henholdsvis ”Viramune to gange daglig”-gruppen og i efavirenzgruppen.
Median age was 34 years and about 64 % were male patients, median CD4 cell count was 170 and 190 cells per mm3 in the Viramune twice daily and efavirenz groups, respectively.
Medianalderen var 34 år og omkring 64 % af patienterne var mænd, median CD4-celletallet var 170 og 190 celler pr mm3 i henholdsvis ”Viramune to gange daglig”-gruppen og i efavirenzgruppen.
Median age was 34 years and about 64% were male patients, median CD4 cell count was 170 and 190 cells per mm3 in the Viramune twice daily and efavirenz groups, respectively.
Medianalderen var 61 år (18-90 år), 65% af patienterne var mænd, og 97% var kaukasiere.
The median age was 61 years (range: 18 to 90 years), 65% of patients were men, and 97% were white.
Medianalderen var 62 år (21 til 85) med 34% 65 år og 7% 75 år.
The median age was 62 years (range: 21 to 85) with 34% 65 years of age and 7% 75 years of age.
Medianalderen var 63 år (39-85) med 44% 65 år og 11% 75 år.
The median age was 63 years (range: 39-85) with 44% 65 years of age and 11% 75 years of age.
Medianalderen var 63,5 år (31 til 84 år), 11 % af patienterne var ≥ 75 år, 49 % var mænd, og 79 % var kaukasere.
The median patient age was 63.5 years (range, 31 to 84 years), 11% of patients were ≥ 75 years of age, 49% were male and 79% were Caucasian.
Medianalderen var 65 år (18-87), 59% var mænd, og 99,5% var kaukasiere.
The median age was 65 years (range: 18-87), 59% were men, and 99.5% were white.
Medianalderen var 68 år (34 til 88 år), 74 % var mænd, og 87 % var kaukasiere.
The median age was 68 years (range, 34; 88), 74% were male and 87% were Caucasian.
Medianalderen var 69 år (interval 41-92), og racefordelingen var 93 % kaukasiere, 4 % sorte, 1 % asiater og 2 % andre.
The median age was 69 years (range 41-92) and the racial distribution was 93% Caucasian, 4% Black, 1% Asian, and 2% Other.
Medianalderen var 71 i MPR+R- og MPR+p-armene, og 72 i MPp+p- armen.
The median age was 71 in the MPR+R and MPR+p arms and 72 in the MPp+p arm.
Medianalderen var 71 år (interval 42-93), og racefordelingen var 77 % kaukasiere, 10 % asiater, 2 % sorte og 11 % andre eller ukendt.
The median age was 71 years (range 42-93) and the racial distribution was 77% Caucasian, 10% Asian, 2% Black and 11% other or unknown races.
Medianalderen var 77 år, og den mediane kreatininclearance var 61 ml/min.
The median age was 77 years and the median creatinine clearance was 61 mL/min.
Medianantallet af cyklusser indgivet pr. patient var 6 (et interval på 1-16) for TCF- armen sammenlignet med 4 (et interval på 1-12) for CF-armen.
The median number of cycles administered per patient was 6 (with a range of 1-16) for the TCF arm compared to 4 (with a range of 1-12) for the CF arm.
Medianc (95 % CI) (måneder)
Medianc(95% CI) (months)
Medianc (Interkvartil interval)
Median (Interquartile range)
Mediandosis pr. injektion til at behandle en blødningsepisode var 27,35 (interkvartilt interval
The median dose per injection to treat a bleeding episode was 27.35 (interquartile range 22.73-32.71) IU/kg.
Mediandosis pr. injektion til at behandle en blødningsepisode var 49,69 (interkvartilt interval 29,41-56,82) IU/kg.
The median dose per injection to treat a bleeding episode was 49.69 (interquartile range 29.41-56.82) IU/kg.
Mediandosis pr. injektion til at opretholde hæmostase i løbet af operationen var 58,3 (interval 45-102) IU/kg.
The median dose per injection to maintain haemostasis during surgery was 58.3 (range 45-102) IU/kg.
Mediandosisen af thalidomid var 217 mg og >40 % af patienterne modtog 9 cyklusser.
The median dose of thalidomide was 217 mg and >40% of patients received 9 cycles.
Mediane (interval) maksimale serumkoncentrationer for asparaginaseaktiviteten var 2.324 E/l (1.625 – 4.819 E/l).
Median (range) maximum serum concentrations of asparaginase activity were 2,324 U/l (1,625 – 4,819 U/l).
Mediane og estimerede rater for OS efter 1 år og 2 år er vist i Tabel 3.
Median and estimated rates of OS at 1 year and 2 years are presented in Table 3.
Mediane, måneder (95% CI)
Mediane, Months (95% CI)
Medianeksponeringen indtil afskæringsdatoen for den primære virknings- og sikkerhedsanalyse var 10,37 måneder (0,03-37,8), og 66,0% af patienterne havde været eksponeret i mindst seks måneder.
The median exposure to the treatment up to the cut-off date of the primary efficacy and safety analysis was 10.37 months (0.03-37.8), with 66.0% of patients having at least six months’ exposure.
Medianen eller de gennemsnitlige EC50-værdier for lamivudin mod laboratoriestammer af hiv-1 lå i intervallet 0,007 - 2,3 M.
The median or mean EC50 values for lamivudine against laboratory strains of HIV-1 ranged from 0.007 to 2.3 M.
Medianen for annualiseret blødningshyppighed (Annualised Bleeding Rates, ABR) hos forsøgspersoner, der kunne evalueres for virkning, var 2,95 (interkvartilt interval 1,01-4,35) for forsøgspersoner i armen med profylakse med fast ugentligt interval, 1,38 (interkvartilt interval 0,00-3,43) for forsøgspersoner i armen med individuelt interval og 17,69 (interkvartilt interval 10,77-23,24) for forsøgspersoner i armen med behandling ved behov.
Median Annualised Bleeding Rates (ABR) in subjects evaluable for efficacy were 2.95 (interquartile range 1.01-4.35) for subjects on prophylaxis fixed weekly interval, 1.38 (interquartile range 0.00-3.43) for subjects on individualized interval and 17.69 (interquartile range 10.77-23.24) for subjects on demand.